VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
VanEck Pharmaceutical ETF · Issued by VanEck
| LLY | Eli Lilly and Co | 19.11% |
| MRK | Merck & Co Inc | 10.96% |
| NVS | Novartis AG ADR | 10.06% |
| PFE | Pfizer Inc | 5.05% |
| BMY | Bristol-Myers Squibb Co | 4.98% |
| NVO | Novo Nordisk AS ADR | 4.92% |
| MCK | McKesson Corp | 4.70% |
| ABBV | AbbVie Inc | 4.48% |
| JNJ | Johnson & Johnson | 4.43% |
| GSK | GSK PLC ADR | 4.13% |
No recent news for PPH. The ingest cron pulls every 15 minutes during market hours.